Calidi Biotherapeutics, Inc. financial data

Symbol
CLDI on NYSE, CLDWW on OTC
Industry
Biological Products, (No Diagnostic Substances)
Location
4475 Executive Drive, Suite 200, San Diego, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
First Light Acquisition Group, Inc. (to 9/19/2023)
Latest financial report
10-K - Q4 2024 - Mar 31, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 32.6 % -31.3%
Debt-to-equity -219 % -525%
Return On Equity 259 % +184%
Return On Assets -255 % -153%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 28.5M shares -19.9%
Common Stock, Shares, Outstanding 20.8M shares +484%
Entity Public Float 14M USD -67.6%
Common Stock, Value, Issued 2K USD +100%
Weighted Average Number of Shares Outstanding, Basic 8.01M shares +375%
Weighted Average Number of Shares Outstanding, Diluted 8.01M shares +375%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 8.88M USD -31.8%
Operating Income (Loss) -21.8M USD +24.9%
Nonoperating Income (Expense) -419K USD -101%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -22.2M USD +24%
Income Tax Expense (Benefit) 14K USD -12.5%
Net Income (Loss) Attributable to Parent -22.1M USD +24.2%
Earnings Per Share, Basic -2.97 USD/shares +82.9%
Earnings Per Share, Diluted -2.97 USD/shares +82.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 9.6M USD
Accounts Receivable, after Allowance for Credit Loss, Current 870 USD
Assets, Current 10.2M USD +138%
Property, Plant and Equipment, Net 869K USD -31.6%
Operating Lease, Right-of-Use Asset 2.93M USD -28%
Other Assets, Noncurrent 152K USD -59.2%
Assets 14.2M USD +41.6%
Accounts Payable, Current 487K USD +1652%
Accrued Liabilities, Current 5.79M USD +1574%
Liabilities, Current 9.5M USD -7.19%
Operating Lease, Liability, Noncurrent 1.85M USD -39.2%
Other Liabilities, Noncurrent 1.5M USD
Liabilities 12.2M USD -33.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax -28K USD +40.4%
Retained Earnings (Accumulated Deficit) -122M USD -22.2%
Stockholders' Equity Attributable to Parent 1.53M USD
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 1.97M USD
Liabilities and Equity 14.2M USD +41.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.83M USD -23.3%
Net Cash Provided by (Used in) Financing Activities 3.01M USD -20.5%
Net Cash Provided by (Used in) Investing Activities -5K USD +96.4%
Common Stock, Shares Authorized 330M shares 0%
Common Stock, Shares, Issued 20.8M shares +484%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -806K USD -247%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 9.81M USD +353%
Interest Paid, Excluding Capitalized Interest, Operating Activities 24K USD +100%
Deferred Tax Assets, Valuation Allowance 29.4M USD +23.2%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure
Deferred Tax Assets, Gross 30.2M USD +20.9%
Operating Lease, Liability 3.05M USD -25.1%
Depreciation 402K USD +2.55%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -22.1M USD +24.4%
Lessee, Operating Lease, Liability, to be Paid 3.46M USD -29.3%
Property, Plant and Equipment, Gross 2.22M USD -1.72%
Operating Lease, Liability, Current 1.2M USD +16.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.51M USD +2.66%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.46M USD +2.67%
Operating Lease, Weighted Average Discount Rate, Percent 0.12 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 406K USD -50.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 485K USD -67.8%
Deferred Tax Assets, Operating Loss Carryforwards 20.2M USD +32.7%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 1M shares 0%
Unrecognized Tax Benefits 1.8M USD +18.6%
Lessee, Operating Lease, Liability, to be Paid, Year Four 2K USD -99.6%
Operating Lease, Payments 349K USD +2.95%
Additional Paid in Capital 123M USD +34.9%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 2.96M USD -38.5%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%